1 / 9

Congestive Heart Failure (CHF) Treatment Devices Market is Anticipated to Reach $14,823.3 Million by 2022

The Global Congestive Heart Failure (CHF) Treatment Devices market was evaluated at $10,127.2 million in 2015, and is estimated to reach $14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period

Spooja
Download Presentation

Congestive Heart Failure (CHF) Treatment Devices Market is Anticipated to Reach $14,823.3 Million by 2022

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Congestive Heart Failure (CHF) Treatment Devices Market by Product Type (Pacemakers (Implantable, Pacemakers), CRT (CRT-P, CRT-D), ICDs (T-ICDs, S-ICDs), VADs (LVAD, RVAD, BIVAD)) - Global Opportunity Analysis and Industry Forecast, 2015 - 2022

  2. Introduction: TheGlobalCongestive Heart Failure (CHF) Treatment Devices market was evaluated at $10,127.2 million in 2015, and is estimated to reach $14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period.Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).

  3. Segment Review The report segments the global CHF treatment devices market based on product type, namely, pacemakers, cardiac resynchronization therapy (CRT) devices, implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). Pacemaker is further segmented into dual-chamber pacemakers and single-chamber pacemakers. CRT devices is segmented into two major types, namely, CRT-P and CRT-D. ICDs is further segmented into transvenous implantable cardioverter defibrillator (T-ICDs) and subcutaneous implantable cardioverter defibrillator (S-ICDs). VADs is also segmented into left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device (BIVAD). ICDs was the highest revenue-generating segment in 2015, owing to the stressful hyperactive lifestyle, unhealthy food habits, and growing number of aging population. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA regions.  Get Sample Report: https://www.alliedmarketresearch.com/request-sample/663

  4. Key Players: • Abiomed, Inc. • Berlin Heart GmbH • Biotronik SE & Co. KG • Boston Scientific Corporation • HeartWare International • Jarvik Heart, Inc. • LivaNova PLC • Medtronic plc • ReliantHeart Inc. • St. Jude Medical, Inc.

  5. Key Benefits for Stakeholders: • The study provides an in-depth analysis of the global CHF treatment devices market with current trends and future estimations to elucidate the imminent investment pockets in the market. • The report provides a quantitative analysis from 2015 to 2022 that would enable the stakeholders to capitalize on prevailing market opportunities. • Extensive analysis of the global CHF treatment devices market, by product, helps in understanding the various types of devices used for the treatment of CHF and other related cardiac conditions.  • Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.

  6. About Us: Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small- & medium-scale enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain. Allied Market Research provides one-stop solution right from data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients understand the significance and impact of market dynamics. The company applies client’s insight on the factors such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligence support to help clients transform into a prominent business firm.

  7. Contact Us: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free (USA/Canada): +1-800-792-5285, +1-503-894-6022, +1-503-446-114 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1⟨855⟩550-5975 help@alliedmarketresearch.com

  8. Thank You View Report: http://hitechnewsdaily.com/2019/07/congestive-heart-failure-chf-treatment-devices-market-is-anticipated-to-reach-14823-3-million-by-2022/

More Related